Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
Type:
Grant
Filed:
December 19, 2012
Date of Patent:
November 1, 2016
Assignee:
DILAFORETTE AB
Inventors:
Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tiddia, Lino Liverani
Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
Type:
Grant
Filed:
December 19, 2012
Date of Patent:
November 1, 2016
Assignee:
DILAFORETTE AB
Inventors:
Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas